Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...

Nearly 32% of Zepbound users lost at least a quarter of their body weight, compared with about 16% of Wegovy users. In both ...

The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

As more doctors and patients turn to the latest weight-loss drugs, researchers are trying to figure out which drug is right ...

The best metric is not weight, but a particularly toxic kind of fat.

Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.

The popular weight loss medications produced different results in patients who participated in a trial, and here’s what ...

A new study shows Zepbound beats Wegovy for weight loss. "It's NOT normal to snore; get it checked out. Sleep apnea worsens ...

In a nutshell Tirzepatide (Mounjaro) produced 20.2% weight loss compared to semaglutide’s (Wegovy) 13.7% after 72 weeks of ...

New data suggests the weight-loss drug Wegovy may significantly reduce the risk of heart disease even before users experience ...

The effects they have on your body and mind vary, as Wegovy flips one appetite switch in your brain, while Mounjaro flips two ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...